K Number
K973799
Device Name
CARDIAC TAGGING TECHNIQUES/MAGNETOM VISION AND MAGNETOM IMPACT
Date Cleared
1998-01-02

(88 days)

Product Code
Regulation Number
892.1000
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Siemens developed Cardiac Tagging pulse sequences for the Magnetom Vision and Impact Systems to allow for the non-invasive evaluation of cardiac wall motion and blood flow. Absence of tag deformation throughout the cardiac cycle is an indicator of dysfunctional myocardium which accompanies a variety of disease states. In addition, Cardiac Tagging may assist in differentiating between fixed thrombus and slowly flowing blood. Cardiac Tagging is intended as an add-on to routine MR imaging examinations of the heart and great vessels. Tagging may provide additional diagnostic information, which in the hands of a qualified physician, can be useful in the diagnosis of disease.
Device Description
The Magnetom Cardiac Tagging Techniques consist of software and sequences designed to apply a series of equally spaced saturation bands to generate a grid on a cardiac image, for use in cardiac evaluation.
More Information

Not Found

No
The summary describes software and sequences for generating a grid on cardiac images, which is a standard MR technique, and does not mention any AI/ML components or related concepts like training/test sets or performance metrics typically associated with AI/ML.

No
The device is used for non-invasive evaluation and diagnosis, providing additional diagnostic information, rather than directly treating or preventing disease.

Yes

Explanation: The "Intended Use / Indications for Use" section states that "Tagging may provide additional diagnostic information, which in the hands of a qualified physician, can be useful in the diagnosis of disease." This directly indicates a diagnostic purpose.

No

The device description explicitly states it consists of "software and sequences designed to apply a series of equally spaced saturation bands to generate a grid on a cardiac image," implying interaction with and control of the Magnetom MR system's hardware to generate the tagging. This is not a standalone software device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The description clearly states that this device uses Magnetic Resonance (MR) imaging to evaluate cardiac wall motion and blood flow non-invasively. It applies saturation bands to generate a grid on a cardiac image.
  • No Sample Analysis: There is no mention of analyzing biological samples taken from the patient. The device works by interacting with the patient's body using magnetic fields and radio waves to generate images.

Therefore, this device falls under the category of a medical imaging device, not an In Vitro Diagnostic.

N/A

Intended Use / Indications for Use

Siemens Cardiac Tagging pulse sequences for the Magnetom Vision and Impact systems allow for the non-invasive evaluation of cardiac wall motion and blood flow.

Siemens developed Cardiac Tagging pulse sequences for the Magnetom Vision and Impact Systems to allow for the non-invasive evaluation of cardiac wall motion and blood flow. Absence of tag deformation throughout the cardiac cycle is an indicator of dysfunctional myocardium which accompanies a variety of disease states. In addition, Cardiac Tagging may assist in differentiating between fixed thrombus and slowly flowing blood.

Cardiac Tagging is intended as an add-on to routine MR imaging examinations of the heart and great vessels. Tagging may provide additional diagnostic information, which in the hands of a qualified physician, can be useful in the diagnosis of disease.

Product codes

LNH

Device Description

The Magnetom Cardiac Tagging Techniques consist of software and sequences designed to apply a series of equally spaced saturation bands to generate a grid on a cardiac image, for use in cardiac evaluation.

The magnet, RF system, and gradient system of the Magnetom Vision and Impact configured with the Cardiac Tagging option are unchanged from that of the standard Magnetom Vision and Impact systems. Introduction of Cardiac Tagging will not affect the technological characteristics of the system, which allows presentation of images and other parameters based upon the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Magnetic Resonance (MR)

Anatomical Site

cardiac, heart and great vessels

Indicated Patient Age Range

Not Found

Intended User / Care Setting

qualified physician

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K900889

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.1000 Magnetic resonance diagnostic device.

(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

0

K97399

510 (k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. JAN - 2 1998 General Information. I.

  • Establishment: Siemens Medical Systems, Inc. · Address: 186 Wood Avenue South Iselin, N.J. 08830 · Registration Number: 2240869 Kathleen M. Rutherford • Contact Person: Manager, Regulatory Submissions (908) 321-4779 October 3, 1997 · Date of Summary Preparation: Device Name: Cardiac Tagging Techniques/ · Trade Name: MAGNETOM Vision, Impact Magnetic Resonance Diagnostic · Classification Name: Device, CFR § 892.1000 Class II · Classification: None established under Section · Performance Standards: 514 of the Food, Drug, and Cosmetic Act.

II. Safety and Effectiveness Information Supporting the Substantial Equivalence Determination.

Device Description:

The Magnetom Cardiac Tagging Techniques consist of software and sequences designed to apply a series of equally spaced saturation bands to generate a grid on a cardiac image, for use in cardiac evaluation.

1

Intended Use

Siemens Cardiac Tagging pulse sequences for the Magnetom Vision and Impact systems allow for the non-invasive evaluation of cardiac wall motion and blood flow.

Technological Characteristics

The magnet, RF system, and gradient system of the Magnetom Vision and Impact configured with the Cardiac Tagging option are unchanged from that of the standard Magnetom Vision and Impact systems. Introduction of Cardiac Tagging will not affect the technological characteristics of the system, which allows presentation of images and other parameters based upon the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance.

General Safety and Effectiveness Concerns:

Operation of the MAGNETOM Vision and Impact systems with the new Cardiac Tagging feature is substantially equivalent to standard operation of the MAGNETOM Vision and Impact system. The following safety parameter action levels:

  • static field strength, ।
  • RF exposure, r

and performance levels:

  • high contrast spatial resolution, -
  • slice thickness, -
  • geometric distortion,
  • -SNR, and
  • image uniformity

specified by the FDA guidance document for MR Diagnostic Devices are unaffected by the modifications described within this notification.

Substantial Equivalence:

Siemens believes that, within the meaning of the Safe Medical Device Act of 1990, MR Cardiac Tagging Techniques are substantially equivalent to Siemens Magnetom Cardiac Cine Techniques which were originally described in premarket notification K900889 which received FDA clearance on 03/23/90.

Kathleen Rutherford
Signature

10/3/97

Date

2

Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of a human figure, represented by three curved lines, positioned to the right of the department's name. The text "DEPARTMENT OF HEALTH & HUMAN" is arranged in a circular fashion around the left side of the logo, with "SERVICES - USA" completing the circle at the bottom.

JAN - 2 1998

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Kathleen Rutherford Manager, Regulatory Submissions Siemens Medical Systems, Inc. 186 Wood Avenue South Iselin, NJ 08830

Re: K973799

Cardiac Tagging Techniques for Magnetom Vision and Impact (MR accessory) Dated: October 3, 1997 Received: October 6, 1997 Regulatory Class: II 21 CFR 892.1000/Procode: 90 LNH

Dear Ms. Rutherford:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the interestore) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

h.J.Liau Yin

Lillian Yin, Ph.D.

Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

3

510(k) Number (if known) K17 3799 -----

Device Name: Cardiac Tagging

Indications for Use:

Siemens developed Cardiac Tagging pulse sequences for the Magnetom Vision and Impact Systems to allow for the non-invasive evaluation of cardiac wall motion and blood flow. Absence of tag deformation throughout the cardiac cycle is an indicator of dysfunctional myocardium which accompanies a variety of disease states. In addition, Cardiac Tagging may assist in differentiating between fixed thrombus and slowly flowing blood.

Cardiac Tagging is intended as an add-on to routine MR imaging examinations of the heart and great vessels. Tagging may provide additional diagnostic information, which in the hands of a qualified physician, can be useful in the diagnosis of disease.

(please do not write below this line- continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation

Prescription Use_

OR

Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________

Kilian Yi

(Division Sign-Off) Division of Reproductive, Abdominal, ENT and Radiological Devices 510(k) Number_